Encyclopedia

PEG-MGF is a pegylated (polyethylene-glycol-conjugated) version of Mechano Growth Factor (MGF), the C-terminal E-domain peptide of the IGF-1Ec splice variant that is naturally expressed within hours of mechanical muscle damage to activate satellite cells. Pegylation extends native MGF's half-life from minutes to hours-to-days. It has essentially no human clinical data and is not FDA-approved; the parent hormone IGF-1 (mecasermin) is separately FDA-approved for a specific pediatric deficiency indication, which should not be conflated with PEG-MGF itself.

MGF (Mechano Growth Factor) is the unique 24-amino-acid C-terminal E-domain peptide produced by alternative splicing of the IGF1 gene, first characterized by Geoffrey Goldspink's laboratory at University College London. Unlike the mature IGF-1 domain (which signals through IGF-1R and is associated with cell proliferation broadly, including in oncology contexts), the MGF E-domain has distinct, more localized biological activity: it is the first IGF-1 splice variant expressed after mechanical muscle damage (within 0-2 hours), peaking at 2-6 hours to activate quiescent satellite cells, before IGF-1Ea expression rises at 6-72 hours to drive differentiation and protein synthesis. Native MGF has an extremely short half-life of approximately 5-7 minutes, severely limiting its practical research utility; PEGylation -- attaching a polyethylene glycol polymer chain -- extends this to hours or days by shielding the peptide from proteolytic degradation and reducing renal clearance, at the cost of introducing a class-wide PEGylation risk: repeated dosing can induce anti-PEG antibodies leading to accelerated clearance on subsequent doses (the 'ABC phenomenon'). PEG-MGF remains entirely preclinical, with animal and cell-culture data on satellite cell activation, and separately-published research on neurogenesis and neuroprotection in brain injury/aging models via the same E-domain peptide. It has no human clinical trial data and is not FDA-approved for any indication.

Mechanism of Action

Activates quiescent muscle satellite cells (the resident stem-cell population responsible for muscle repair and hypertrophy), expanding the progenitor pool as the first-responding IGF-1 splice variant after mechanical damage. This is mechanistically distinct from mature IGF-1 signaling through IGF-1R (implicated more broadly in cell proliferation, including tumor growth pathways) and from myostatin-inhibition approaches (e.g., follistatin), which remove an anti-growth brake rather than actively recruiting progenitor cells. Separately studied for neurogenic and neuroprotective activity via the same E-domain peptide in brain injury/aging models.